Ibrunat 140mg Tablet

• Blood cancer (Chronic lymphocytic leukemia
• Mantle-cell lymphoma

Ibrunat 140mg tablet causes certain side effects that are harmful to the body. Some of them are mild, and some are acute. If the symptoms persist or worsen, it is important to visit a healthcare professional immediately. Common ones include:

• Muscle and bone pain
• Rash and bruising
• Mouth sores
• Pneumonia
• Fever, chills
• Breathlessness
• Constipation
• Dizziness
• Body pain
• Swollen ankles and feet
• Increased creatinine levels in the blood

• Bleeding problems
• Infections
• Decrease in blood cell counts
• Heart problems
• High BP
• Nausea
• Vomiting
• Diarrhea
• Tiredness

Ibrunat 140mg tablet should be taken at the same time everyday. The medication is taken orally with or without food as directed by the healthcare professional. Do not chew, crush or break the tablet just take it with a whole glass of water. Never skip or overdose on the missed one without consultation with a doctor as this may cause side effects that could interfere with the effectiveness and safety of the treatment. Always consult with the healthcare professional before using the medicine.

The BTK enzyme plays an important role in B cell receptor signaling. In normal B cells, BTK function is helpful but in cancerous B cells, BTK activity becomes abnormal, causing cancer cells to grow and survive more than they should. Ibrunat 140mg tablet contains BTK inhibitors that block the enzyme and prevent the body from cancer growth and prevent the body from further growing cancer.

• Cameron, F., & Sanford, M. (2014). Ibrutinib: first global approval. Drugs, 74(2), 263-271. https://pubmed.ncbi.nlm.nih.gov/24464309/
• Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., ... & Kipps, T. J. (2015). Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. New England Journal of Medicine, 373(25), 2425-2437. https://pubmed.ncbi.nlm.nih.gov/26639149/
• Charalambous, A., Schwarzbich, M. A., & Witzens-Harig, M. (2018). Ibrutinib. In Small Molecules in Hematology (pp. 133-168). Cham: Springer International Publishing. https://pubmed.ncbi.nlm.nih.gov/30069629/
• Shatzel, J. J., Olson, S. R., Tao, D. L., McCarty, O. J., Danilov, A. V., & DeLoughery, T. G. (2017). Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies. Journal of thrombosis and haemostasis, 15(5), 835-847. https://pubmed.ncbi.nlm.nih.gov/28182323/
• Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O’Brien, S., Barrientos, J., ... & Tallman, M. (2019). Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. New England Journal of Medicine, 381(5), 432-443. https://pubmed.ncbi.nlm.nih.gov/31365801/